Simplicity Wealth LLC Has $2.22 Million Stake in Abbott Laboratories $ABT

Simplicity Wealth LLC lowered its position in shares of Abbott Laboratories (NYSE:ABT) by 48.6% during the third quarter, HoldingsChannel reports. The fund owned 16,552 shares of the healthcare product maker’s stock after selling 15,674 shares during the quarter. Simplicity Wealth LLC’s holdings in Abbott Laboratories were worth $2,217,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. IMG Wealth Management Inc. increased its stake in shares of Abbott Laboratories by 759.1% in the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after buying an additional 167 shares during the period. Anfield Capital Management LLC grew its holdings in Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after acquiring an additional 104 shares during the last quarter. Delos Wealth Advisors LLC acquired a new position in Abbott Laboratories in the 2nd quarter valued at approximately $32,000. Curio Wealth LLC raised its stake in shares of Abbott Laboratories by 15,250.0% during the second quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker’s stock valued at $42,000 after acquiring an additional 305 shares during the last quarter. Finally, Pineridge Advisors LLC lifted its holdings in shares of Abbott Laboratories by 34.6% during the second quarter. Pineridge Advisors LLC now owns 315 shares of the healthcare product maker’s stock worth $43,000 after purchasing an additional 81 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $108.50 on Friday. The stock has a market capitalization of $188.67 billion, a price-to-earnings ratio of 13.60, a PEG ratio of 2.00 and a beta of 0.72. Abbott Laboratories has a 52-week low of $105.78 and a 52-week high of $141.23. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. The stock’s 50 day moving average price is $125.23 and its two-hundred day moving average price is $128.54.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. The company had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. Abbott Laboratories’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be given a dividend of $0.63 per share. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date of this dividend is Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s payout ratio is currently 31.58%.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Med‑tech / devices strength helped offset weakness elsewhere — management said Devices/MedTech delivered solid growth in Q4, cushioning the hit from Nutrition and Diagnostics. Read More.
• Positive Sentiment: Adjusted EPS and margins improved — adjusted EPS grew ~12% and matched street expectations, with margin gains driven by product mix and cost improvements. This supports the company’s cash generation and capital-return capacity. Read More.
• Neutral Sentiment: Reported EPS met consensus ($1.50), limiting the severity of the selloff from an earnings-surprise perspective. Read More.
• Negative Sentiment: Revenue missed expectations — Q4 revenue was below consensus ($~11.5B vs. ~$11.8B est), driven by a contraction in Nutrition (~‑9%) and weakness in Diagnostics (lower COVID testing and aid-related volatility). That top‑line miss is the main catalyst for the decline. Read More.
• Negative Sentiment: Guidance came in slightly below street models — Q1 EPS guide (1.120–1.180) and FY 2026 adjusted EPS (5.550–5.800) skated under consensus, which amplified selling pressure given the revenue shortfall. Read More.
• Negative Sentiment: Unusual bearish options activity — traders bought a large volume of puts (reported ~80,600), signaling elevated short‑term hedging or directional bearish bets that can accelerate downward moves in the stock.
• Negative Sentiment: Market reaction and media coverage — widespread headlines on the revenue miss and weaker outlook pushed the shares lower and into fresh downside territory, with analysts noting the pullback even as most maintain constructive long‑term views. Read More.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a report on Thursday, November 20th. Evercore ISI increased their price target on Abbott Laboratories from $142.00 to $144.00 and gave the company an “outperform” rating in a research note on Monday, January 5th. Raymond James Financial lifted their price objective on Abbott Laboratories from $141.00 to $146.00 and gave the stock an “outperform” rating in a research note on Thursday, October 16th. Royal Bank Of Canada reissued an “outperform” rating and set a $147.00 target price on shares of Abbott Laboratories in a research report on Thursday, October 16th. Finally, BTIG Research restated a “buy” rating and issued a $145.00 price target on shares of Abbott Laboratories in a research report on Thursday, November 20th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $147.39.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.